Tue, February 11, 2025
Mon, February 10, 2025
Sun, February 9, 2025
Sat, February 8, 2025
[ Sat, Feb 08th ] - techUK
AI Action Summit: Day 1
Fri, February 7, 2025
[ Fri, Feb 07th ] - Indiatimes
RBI MPC Meeting Live
Thu, February 6, 2025
Wed, February 5, 2025
Tue, February 4, 2025
Mon, February 3, 2025

Health Rounds: Vaccine keeps advanced kidney cancer from recurring


//business-finance.news-articles.net/content/202 .. keeps-advanced-kidney-cancer-from-recurring.html
Published in Business and Finance on by Reuters   Print publication without navigation

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still cancer-free years later in a small early-stage trial, researchers reported in Nature.

The article from Reuters discusses a new study presented at the American Society of Clinical Oncology's Genitourinary Cancers Symposium, which found that a personalized mRNA vaccine, when combined with Merck's immunotherapy Keytruda, significantly reduced the risk of recurrence or death in patients with advanced kidney cancer. The study involved 104 patients who had their tumors surgically removed; half received the vaccine plus Keytruda, while the other half received Keytruda alone. After about two years, 78.6% of those treated with the combination therapy were alive and cancer-free, compared to 58.8% in the Keytruda-only group. This represents a 47% reduction in the risk of recurrence or death. The vaccine, developed by Moderna, uses the same technology as its COVID-19 vaccine, tailoring it to the genetic makeup of each patient's tumor to enhance the immune response against cancer cells.

Read the Full Reuters Article at:
[ https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-vaccine-keeps-advanced-kidney-cancer-recurring-2025-02-07/ ]

Publication Contributing Sources